EGFR and neoplasm: One high-throughput immuno-oncology screen identified the EGFR inhibitor erlotinib as a potent enhancer of antigen-specific CTL tumor cell killing, synergizing with anti-PD-1 checkpoint inhibition to suppress colon cancer growth [106].